TY  - JOUR
T1  - CYp2c19 genotype and cardiovascular events
AU  - Shuldiner AR, Vesely MR, Fisch A
Y1  - 2012/04/11
N1  - 10.1001/jama.2012.443
JO  - JAMA
SP  - 1482
EP  - 1485
VL  - 307
IS  - 14
N2  - 
To the Editor:  The recent meta-analysis by Dr Holmes and colleagues1 concluding that CYP2C19 genotype is not a significant predictor of clinical outcomes in patients treated with clopidogrel contrasts with a previous meta-analysis2 and a large body of pharmacokinetic and pharmacodynamic evidence,3 including a genome-wide association study.4 The authors cite small-study bias and inability to evaluate effect modification in treatment-only studies as reasons underlying the discrepant findings.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.443
UR  - http://dx.doi.org/10.1001/jama.2012.443
ER  -